Effectiveness and Safety of Sacubitril/Valsartan in Patients with Chronic Kidney Disease-A Real-World Experience.

ABSTRACT:

Background

data regarding the effectiveness and safety of sacubitril/valsartan in heart failure and reduced ejection fraction (HFrEF) patients with chronic kidney disease (CKD) are scarse.

Objective

to evaluate the effectiveness and safety of sacubitril/valsartan in HFrEF and CKD in a real-world population.

Methods

we included consecutive ambulatory HFrEF patients that initiated sacubitril/valsartan between February 2017 and October 2020, stratified by CKD (KDIGO stage 5 excluded).

Primary outcomes

the incidence rate per 100 patient-years and the annualized length of stay (LOS) of acute decompensated HF hospitalizations (HFH).

Secondary outcomes

all-cause mortality, NYHA improvement, and titration of sacubitril/valsartan.

Results

We included 179 p

SUBMITTER: Pereira SC 

PROVIDER: S-EPMC9967392 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature